Market Cap
$9.2B
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
$64.19 ▼ -0.93%
Prev close $64.79Market cap$9.2B
ConsensusStrong Buy
12-mo target$107.23 (+67.1%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (2 insiders)28 New Institutional Positions22 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ARWR right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$7.9B
Inst. Activity
28 buys / 22 sells
Insider Activity
$0.00 buy / $3.7M sell
Insider Net $
-$3.7M
SEC Reports
3
Price chart 30d -25.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 short_volume
Sep 10, 2026 SEC Short Volume: ARWR — 59.4% short (0.4M / 0.7M)
Short: 433,347 | Exempt: 43,600 | TRF Vol: 729,532 | Short Ratio: 59.4% | Off-exchange volume (dark
ARWR saw a mixed institutional cluster in Q2 2026 with 42 buyers accumulating $452.7M and 43 sellers reducing by $147.6M
INST-CLUSTER — Impact 5/10
Two directors at Arrowhead Pharmaceuticals sold a combined $1.19M in open-market sales on August 18, 2026. This is a sma
CLUSTER — Impact 2/10
Aug 18, 2026 Insider
OLUKOTUN ADEOYE Y sold 2,000 shares
Director @ $86.96 ($173.9K)
Aug 18, 2026 Insider
PERRY MICHAEL S sold 11,600 shares
Director @ $87.30 ($1.0M)
Jun 30, 2026 Inst.
NORGES BANK — NEW
3,896,536 shares ($317.6M)
Jun 30, 2026 Inst.
Jun 16, 2026 SEC FIRST TRUST ADVISORS LP — DOUBLED
1,352,918 shares ($110.3M)
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manage
8-K — Impact 2/10
Analyst ratings buy % +26.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | Citigroup | INITIATE | Buy | 55% |
| Sep 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 31, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Aug 31, 2026 | RBC Capital | REITERATE | Outperform | 55% |
| Aug 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 30, 2026 | B. Riley Securities | MAINTAIN | Buy | 54% |
| Jul 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 23, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jul 23, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Jul 22, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 4 | 13 | 3 | 0 | 0 | 85% | |
| Jun 1, 2026 | 4 | 13 | 3 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 12 | 3 | 0 | 0 | 84% | |
| Apr 1, 2026 | 4 | 11 | 4 | 0 | 0 | 79% | |
| Mar 1, 2026 | 4 | 11 | 4 | 0 | 0 | 79% | |
| Feb 1, 2026 | 4 | 11 | 5 | 0 | 0 | 75% |
Price targets
Where 13 covering analysts think ARWR trades over the next 12 months.
$107.23 +67.1% upside Strong Buy
Current$64.19 Low$74.00 Median$104.00 High$126.00 13 analysts
$74.00$126.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 2 neutral · avg impact 3.0/10.
MIXEDINST-CLUSTER5/10
ARWR saw a mixed institutional cluster in Q2 2026 with 42 buyers accumulating $452.7M and 43 sellers
Sep 10, 2026
NEUTRALCLUSTER2/10
Two directors at Arrowhead Pharmaceuticals sold a combined $1.19M in open-market sales on August 18,
Aug 21, 2026
NEUTRAL8-K2/10
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Mor
Jun 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
Clinical Trial
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Phase Phase 3 — COMPLETED
Sep 24, 2026
short_volume
Short Volume: ARWR — 59.4% short (0.4M / 0.7M)
Short: 433,347 | Exempt: 43,600 | TRF Vol: 729,532 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: ARWR — 57.0% short (0.6M / 1.1M)
Short: 621,488 | Exempt: 7,019 | TRF Vol: 1,090,318 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: ARWR — 60.5% short (0.5M / 0.9M)
Short: 529,269 | Exempt: 1 | TRF Vol: 875,472 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: ARWR — 64.3% short (0.8M / 1.2M)
Short: 763,320 | Exempt: 0 | TRF Vol: 1,187,060 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.54 | $-3.00–$-0.35 | -753.0% | -0.9% | 0↑ 5↓ | $0.1B | 14 |
| Next Q | $-1.37 | $-1.75–$-1.00 | -721.0% | +3.2% | 0↑ 1↓ | $0.0B | 7 |
| Current FY | $-3.54 | $-5.14–$-2.45 | -35300.4% | -1.0% | 0↑ 6↓ | $0.5B | 14 |
| Next FY | $-4.93 | $-6.58–$-2.66 | -39.3% | -1.3% | 0↑ 6↓ | $0.3B | 14 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.535 | — |
| 7d ago | $-1.540 | +0.005 |
| 30d ago | $-1.521 | -0.014 |
| 60d ago | $-1.174 | -0.361 |
| 90d ago | $-1.125 | -0.411 |
Institutional ownership
Which big funds own ARWR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $7.9B total value (97,009,429 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, Avoro. Net buying activity: 28 institutions added/increased vs 22 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 14,830,553 | $1.2B | 15.3% | — |
| Avoro Capital Advisors LLC | 11,355,555 | $925.6M | 11.7% | — |
| FMR LLC | 8,039,804 | $655.3M | 8.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,351,355 | $517.7M | 6.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,110,953 | $498.1M | 6.3% | — |
| STATE STREET CORP | 5,694,640 | $464.2M | 5.9% | — |
| NORGES BANK | 3,896,536 | $317.6M | 4.0% | NEW |
| Invesco Ltd. | 3,883,976 | $316.6M | 4.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,530,612 | $298.8M | 3.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 3,896,536 | — | $317.6M |
| FIRST TRUST ADVISORS LP | DOUBLED | 149,148 | 1,352,918 | +807.1% | $110.3M |
| NORTHERN TRUST CORP | TRIM | 1,655,837 | 1,192,868 | -28.0% | $97.2M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 608,531 | 1,181,608 | +94.2% | $96.3M |
| GOLDMAN SACHS GROUP INC | TRIM | 1,739,923 | 1,150,007 | -33.9% | $93.7M |
| Holocene Advisors, LP | NEW | — | 1,106,177 | — | $90.2M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 1,330,996 | 964,479 | -27.5% | $78.6M |
| UBS Group AG | TRIM | 1,336,271 | 861,520 | -35.5% | $70.2M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 836,981 | 625,569 | -25.3% | $51.0M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 378,833 | 596,573 | +57.5% | $48.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 9 transactions. Net -$3.7M — $0.00 bought, $3.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | OLUKOTUN ADEOYE Y | Director | SELL | 2,000 | $86.96 | $173.9K |
| Aug 18, 2026 | PERRY MICHAEL S | Director | SELL | 11,600 | $87.30 | $1.0M |
| Jun 15, 2026 | Cohen Matthew Gregory | Director | AWARD | 11,882 | — | — |
| May 12, 2026 | Lu Hongbo | Director | SELL | 2,970 | $76.88 | $228.3K |
| Apr 23, 2026 | Hamilton James C | Chief Medical Officer | SELL | 10,000 | $75.00 | $750.0K |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | SELL | 8,730 | $71.92 | $627.9K |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | SELL | 1,157 | $70.45 | $81.5K |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | SELL | 3,208 | $70.11 | $224.9K |
| Mar 5, 2026 | Hamilton James C | Chief Medical Officer | SELL | 10,000 | $64.19 | $641.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ARWR.
Shares short
9,272,290
Settlement Sep 15, 2026
Change vs prior
-1.6%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈6.6%
Estimate — not % of float
All ARWR filing & press-release reports (3)
- INST-CLUSTER reportSep 10, 2026
- CLUSTER reportAug 21, 2026
- 8-K reportJun 16, 2026